All questions
Safety: Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention 10 questions · 4 sources
Safety questions that apply to every indication of Shingrix are on Shingrix (Zoster Vaccine Recombinant, Adjuvanted), all indications: Safety .
Side effects Shingrix side effects: which are most common in adults 50 and older? Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older
How common are Shingrix side effects vs placebo by age in adults 50 and older? Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older
“Solicited local and general adverse reactions within 7 days of vaccination (data from ZOE-50 & pooled analysis from ZOE-50 & ZOE-70)
Age 50-59 years old 60-69 years old ≥70 years old
SHINGRIX % Placebo % SHINGRIX % Placebo % SHINGRIX % Placebo %
Local adverse reactions n=1315 n=1312 n=1311 n=1305 n=2258 n=2263
Pain 88 14 83 11 69 9
Pain, Grade 3* 10 1 7 1 4 0.2
Redness 39 1 38 2 38 1
Redness, >100 mm 3 0 3 0 3 0
Swelling 31 1 27 1 23 1
Swelling, >100 mm 1 0 1 0 1 0
General
adverse reactions n=1315 n=1312 n=1309 n=1305 n=2252 n=2264
Myalgia 57 15 49 11 35 10
Myalgia, Grade 3† 9 1 5 1 3 0.4
Fatigue 57 20 46 17 37 14
Fatigue, Grade 3† 9 2 5 1 4 1
Headache 51 22 40 16 29 12
Headache, Grade 3† 6 2 4 0.2 2 0.4
Shivering 36 7 30 6 20 5
Shivering, Grade 3† 7 0.2 5 0.3 2 0.3
Fever‡ 28 3 24 3 14 3
Fever, Grade 3§ 0.4 0.2 1 0.2 0.1 0.1
GI‖ 24 11 17 9 14 8
GI, Grade 3† 2 1 1 1 1 0.4
In ZOE-50 and ZOE-70, data on solicited local and general adverse reactions were collected using standardized diary cards for 7 days following each vaccine dose or placebo (ie, day of vaccination and the next 6 days) in a subset of subjects (n=4886 receiving SHINGRIX, n=4881 receiving placebo with at least 1 documented dose). Data for subjects 50-59 years and 60-69 years are from ZOE-50 and data for subjects 70 years and older are based on pooled data from ZOE-50 and ZOE-70.
*
Grade 3 pain defined as significant pain at rest; prevents normal everyday activities.
†
Grade 3 myalgia, fatigue, headache, shivering, and GI: defined as preventing normal activity.
‡
Fever defined as ≥37.5°C/99.5°F for oral, axillary, or tympanic route, or ≥38°C/100.4°F for rectal route.
§
Grade 3 fever defined as >39.0°C/102.2°F.
‖
Included nausea, vomiting, diarrhea, and/or abdominal pain.
n=number of subjects with at least 1 documented dose of either SHINGRIX or placebo included in the total vaccinated cohort for safety.” (opens the source at this quote in a new tab) Copy Flag
Are Shingrix side effects worse after the second dose in adults 50 and older? Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older
“There were no differences in the proportions of subjects reporting any or Grade 3 solicited local reactions
between Dose 1 and Dose 2. Headache and shivering were reported more frequently by subjects after Dose 2
(28% and 21%, respectively) compared with Dose 1 (24% and 14%, respectively). Grade 3 solicited general
adverse reactions (headache, shivering, myalgia, and fatigue) were reported more frequently by subjects after
Dose 2 (2.3%, 3%, 4%, and 4%, respectively) compared with Dose 1 (1.4%, 1.4%, 2.3%, and 2.4%,
respectively).” (opens the source at this quote in a new tab) Copy Flag
What other Shingrix side effects occurred within 30 days in adults 50 and older? Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older
Shingrix serious adverse events vs placebo: how common in adults 50 and older? Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older
What are Shingrix side effects in immunocompromised adults 18 and older? Applies to Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy
Note: The percentages are from the auHSCT study (NCT01610414), the largest of the 6 studies in immunocompromised adults. The first passage is from the Patient Counseling page and the others from the Safety Profile page of the immunocompromised section of the Shingrix HCP site.
Shingrix serious adverse events: how common in immunocompromised adults 18 and older? Applies to Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy
Safety Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older
Did Shingrix affect relapse, graft rejection, or HIV vs placebo in immunocompromised adults? Applies to Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy
Note: The Safety Profile page of the immunocompromised section of the Shingrix HCP site gives the Shingrix denominator of the NCT01610414 study as 992 in its table; the Prescribing Information gives 315 of 922.
Warnings Does Shingrix increase the risk of Guillain-Barré syndrome (GBS)? Applies to Medicare beneficiaries aged 65 years or older (postmarketing observational studies of Guillain-Barre syndrome)
“In one study, using Medicare claims data, from October 2017 through February 2020, vaccinations with
SHINGRIX among beneficiaries were identified through National Drug Codes, and potential cases of
hospitalized GBS among recipients of SHINGRIX were identified through International Classification of
Diseases codes.
The risk of GBS following vaccination with SHINGRIX was assessed in self-controlled case series analyses
using a risk window of 1 to 42 days postvaccination and a control window of 43 to 183 days postvaccination.
Medical record review of GBS cases was conducted to estimate the Positive Predictive Value (PPV) of the
claims algorithm. PPV-adjusted risk estimates were calculated by imputing GBS status for all claims-identified
cases. These analyses included GBS cases in which other vaccinations were administered the same day or
within 42 days of SHINGRIX. The primary analysis, which did not distinguish between doses, found an
increased risk of GBS during the 42 days following vaccination with SHINGRIX, with an estimated 3 excess
cases (95% confidence interval [CI]: 0.6, 5.6) of GBS per million doses administered to adults aged 65 years or
older. In secondary analyses, an increased risk of GBS was observed during the 42 days following the first dose
of SHINGRIX, with an estimated 6 excess cases (95% CI: 3.4, 9.6) of GBS per million doses administered to
adults aged 65 years or older, and no increased risk of GBS was observed following the second dose of
SHINGRIX.
A separate similarly-designed study also evaluated the association between vaccination with SHINGRIX and
GBS among Medicare beneficiaries aged 65 years or older. Using Medicare claims data, from January 2018
through December 2020, vaccinations with SHINGRIX among beneficiaries were identified through National
Drug Codes and Current Procedural Terminology codes. Potential cases of hospitalized GBS among recipients
of SHINGRIX were identified through International Classification of Diseases codes.” (opens the source at this quote in a new tab) Copy Flag
“The primary
and secondary analyses included GBS cases in which other vaccinations were administered the same day or
within 42 days of SHINGRIX. The primary analysis, which did not distinguish between doses, found an
increased risk of GBS during the 42 days following vaccination with SHINGRIX, with an estimated 7 excess
cases (95% CI 4.4, 8.0) of GBS per million doses administered to adults aged 65 years or older. This analysis of
GBS diagnoses in claims data was supported by a post hoc analysis excluding GBS cases in individuals who
received pneumococcal, influenza, and/or tetanus, diphtheria and pertussis (Tdap) vaccines on the same day or
in the 42 days prior to SHINGRIX vaccination. In secondary analyses, an increased risk of GBS was observed
during the 42 days following the first dose of SHINGRIX, with an estimated 12 excess cases (95% CI 8.9, 13.4)
of GBS per million doses administered to adults aged 65 years or older, and no increased risk of GBS was
observed following the second dose of SHINGRIX.” (opens the source at this quote in a new tab) Copy Flag
Note: The Prescribing Information lists this Guillain-Barré syndrome warning (section 5.2) under Recent Major Changes, dated 2/2026.